Long-Term Management of Hepatitis C-Seropositive Subjects with AntiOxidant Biofactor (AOB®), a Fermented Food Supplement
スポンサーリンク
概要
- 論文の詳細を見る
The efficacy of AntiOxidant Biofactor (AOB(R)) for the management of apparently healthy subjects with chronic hepatitis C infection was investigated. A total of 60 subjects (35 males, 25 females) participated in the trial. AOB was given orally in 2 packs (3g per pack) 3 times per day. 17 subjects had taken AOB for 3 years, 31 subjects up to 2 years, and 41 subjects up to one year. The initial mean (SD) serum alamine aminotransferase (ALT) level was 46.3+/-35.4IU/L, and significant (p0.05, paired t-test) reductions in the mean serum ALT levels were observed at 6 months (38.6+/-21.5IU/L), 18 months (31.9+/-18.1IU/L), 2 years (31.2+/-14.6IU/L), and 3 years (28.0+/-15.9IU/L). Those presenting with high serum ALT levels (30 subjects) demonstrated significant levels (p0.05, paired t-test) of reduction in the mean serum ALT levels at 6, 12, 18, 24, and 36 months of treatment. No side effects were observed and the AOB treatment was well tolerated by all subjects.
論文 | ランダム
- センチニクバエ成虫の齢と誘虫灯への反応に関する一事例
- 生体蛍光標識による感染初期段階の内部寄生性植物線虫の植物組織内観察
- Pure Red Cell Aplasia and Myasthenia Gravis with Recurrent Thymoma
- 経皮酸素圧および皮膚灌流圧の測定による重症肢虚血の評価 (Evaluation of Critical Limb Ischemia by Transcutaneous Oxygen Pressure and Skin Perfusion Pressure Measurement)
- A Granulomatous Liver Abscess Which Developed After a Toothpick Penetrated the Gastrointestinal Tract : Report of a Case